1-5 of 5
Rowena Henderson
Close
Sort by
Journal Articles

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Charlotte Pawlyn, Tom Menzies, Faith E Davies, Ruth M. de Tute, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Mark T Drayson, Roger G Owen, David Cairns, Gareth J. Morgan, Graham Jackson
Journal: Blood
Blood (2022) 140 (Supplement 1): 1371–1372.
https://doi.org/10.1182/blood-2022-165376
Published: 2022
Journal Articles

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

Gordon Cook, Charlotte Pawlyn, Kara-Louise Royle, Amy Beth Coulson, Jennifer Bird, Stella Bowcock, Matthew W Jenner, Bhuvan Kishore, Christopher Parrish, Neil K Rabin, Phillip Best, Sharon Gillson, Rowena Henderson, Catherine Olivier, Martin F. Kaiser, Ruth M. de Tute, Roger G Owen, Mark T Drayson, John R Jones, Bryony Dawkins, David Meads, David Cairns, Graham Jackson
Journal: Blood
Blood (2021) 138 (Supplement 1): 81.
https://doi.org/10.1182/blood-2021-146650
Published: 2021
Journal Articles

Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Tom Menzies, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Roger G Owen, Mark T Drayson, David Cairns, Gareth J. Morgan, Graham Jackson
Journal: Blood
Blood (2021) 138 (Supplement 1): 2907.
https://doi.org/10.1182/blood-2021-151102
Published: 2021
Journal Articles

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV

David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Kara-Louise Royle, MSc, Phillip Best, Jenny Bird, MD, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Bryony Dawkins, BA, MSc, Mark T Drayson, MB ChB, PhD FRCPath, Rowena Henderson, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Bhuvan Kishore, MB BS, MRCP, FRCPath, David Meads, Ba, MSc, PhD, Rebecca Mottram, BA, BSc, Neil K Rabin, Roger G. Owen, MD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gordon Cook
Journal: Blood
Blood (2019) 134 (Supplement_1): 3153.
https://doi.org/10.1182/blood-2019-126207
Published: 2019
Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 904.
https://doi.org/10.1182/blood.V130.Suppl_1.904.904
Published: 2017